Press Releases

Efforts Aimed to Help Sustain the Environment, Boost Employee Health & Wellness NUTLEY, N.J., Aug. 17, 2023 /PRNewswire/ -- Eisai Inc., the United States-based pharmaceutical subsidiary of Eisai...

Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) announced today that it has entered into an agreement to transfer the United States (U.S.) commercial rights for the...

State-of-the-art Eisai US hhceco Center underscores New Jersey as the premier life science hub NUTLEY, N.J., Aug. 18, 2022 /PRNewswire/ -- Eisai Inc., the U.S. pharmaceutical subsidiary of Eisai...

Thomas D. Fagan Jr. Appointed Vice President, U.S. Alzheimer's Disease Commercial at Eisai Inc. NUTLEY, N.J., July 27, 2022 /PRNewswire/ -- Eisai Inc., the U.S. pharmaceutical subsidiary of Eisai...

Eisai Inc., the U.S. pharmaceutical subsidiary of Eisai Co., Ltd., today announced the expansion of its leadership team to include Tricia Brooks as Vice President & Head of Office, Government...

Eisai today announced that H3 Biomedicine (H3), its cancer genomics-based drug discovery subsidiary company located in Cambridge, Mass., has appointed a new executive leadership team. Ping Zhu,...

Eisai Inc., the U.S. pharmaceutical subsidiary of Eisai Co., Ltd., today announces the appointment of Janna Hutz, Ph.D., as President of the Eisai Center for Genetics Guided Dementia Discovery...

Eisai Inc., the U.S. pharmaceutical subsidiary of Eisai Co., Ltd., today announced the immediate appointment of Andree Amelsberg, M.D., MBA, as Vice President, U.S. Medical Affairs, Oncology...

Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) announced that its animation “Leave No One Behind－Disease of Neglected People” which features activities for the...

Eisai Inc., the U.S. pharmaceutical subsidiary of Eisai Co., Ltd. and BioLabs announced today the launch of the Eisai Innovation Center BioLabs, a shared lab and office space for start-ups aiming...